We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current LAB market cap is 609.25M. The company's latest EPS is USD -0.2573 and P/E is -8.36.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 25.12M | 27.67M | 25.37M | 28.19M | 45.54M |
| Operating Income | -16.59M | -17.45M | -21.17M | -21.39M | -60.18M |
| Net Income | -16.84M | -17.04M | -21M | -19.78M | -78.17M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 117.24M | 138.14M | 130.58M | 97.95M | 106.34M |
| Operating Income | -51.84M | -51.04M | -67.46M | -116.21M | -76.6M |
| Net Income | -64.79M | -53.02M | -59.24M | -190.1M | -74.66M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 371.65M | 355.83M | 339.29M | 323.07M | 777.67M |
| Total Liabilities | 157.55M | 157.96M | 159.75M | 159.87M | 200.35M |
| Total Equity | -97.15M | -113.39M | -131.72M | -148.05M | 577.32M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 264.81M | 324.76M | 275.21M | 390.31M | 323.07M |
| Total Liabilities | 111.2M | 185.71M | 180.62M | 160.52M | 159.87M |
| Total Equity | 153.61M | 139.05M | 94.6M | -81.47M | -148.05M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -8.49M | -17.81M | -29.23M | -43.29M | -62.48M |
| Investing | 43.15M | 83.28M | 33.35M | 20.24M | 318.08M |
| Financing | -2.56M | -4.64M | -5.81M | -6.81M | -19.73M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -35.21M | -15.42M | -44.06M | -89.37M | -43.29M |
| Investing | -39.3M | 39.98M | -11.95M | -88.13M | 20.24M |
| Financing | 2.79M | 20.86M | 15.96M | 230.76M | -6.81M |
| Market Cap | 609.25M |
| Price to Earnings Ratio | -8.36 |
| Price to Sales Ratio | 5.87 |
| Price to Cash Ratio | 12.07 |
| Price to Book Ratio | 3.82 |
| Dividend Yield | - |
| Shares Outstanding | 290.12M |
| Average Volume (1 week) | 2.01M |
| Average Volume (1 Month) | 2.05M |
| 52 Week Change | -7.89% |
| 52 Week High | 3.16 |
| 52 Week Low | 1.57 |
| Spread (Intraday) | 0.3 (12.5%) |
| Company Name | Standard BioTools Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.fluidigm.com |
| Industry | lab analytical instruments (3826) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
